Privileged Communication in Forensic Medicine

Definition

A privileged communication may be defined, in a general manner, as a communication made by a doctor to a proper authority who has corresponding legal, social and moral duties to protect the public.

• Parikh's Textbook of Medical Jurisprudence, p. 53

Key Conditions for a Valid Privileged Communication

1. The statement must be made bona fide (in good faith) upon any subject matter by a doctor to the concerned authority.
2. The communication must be made to a person having direct interest in it, or one who has a duty in reference to it. If made to more than one person, or to a person without direct interest, the plea of privilege fails.
3. The doctor should first persuade the patient to give consent before notifying the authority. If the doctor discloses professional secrets to protect community interest (under a moral and social obligation), he will not be liable to damages.
4. The facts should be written and sent in a sealed cover marked "Privileged Communication" to the proper authority.

• The Essentials of Forensic Medicine and Toxicology, 36th ed.

Circumstances That Justify Privileged Communication

1. In a Court of Law

2. Moral or Social Duty

3. In the Doctor's Own Interest (Statutory Duty)

• Must notify births, deaths, communicable diseases
• Must notify food poisoning from restaurants or contamination of public water
• Must notify homicidal poisoning to the police

4. Responsibility in Criminal Matters

5. Other Special Cases

• Employer-Employee reports: When a servant is sent by an employer for examination, the result may be communicated (privileged) to the employer - but only regarding fitness for service, necessity for leave, or extent of disability.
• Insurance reports: A doctor may report findings (e.g., high blood pressure) during an insurance examination. However, if the doctor has prior knowledge of a disease from a previous consultation, he cannot disclose that prior knowledge - it would amount to a breach of professional secrecy. He should instead refuse to conduct the examination.
• Inquiries by insurance companies, solicitors, or others: A doctor should not answer such queries without the patient's explicit consent. Even parents and relatives are not entitled to know the results of examination of adult family members.

Landmark Case - Breach of Professional Secrecy (Dr. Playfair's Case)

• Parikh's Textbook of Medical Jurisprudence, p. 53

Privileged Communication vs. Professional Secrecy

Key Exam Points (MCQ Focus)

• Privileged communication is an exception to professional secrecy, not a violation of it.
• It must be made to the proper authority with a direct interest - not to the general public.
• The doctor must first attempt to get patient's consent before disclosing.
• Communication is sent in a sealed cover marked "Privileged Communication."
• Notifiable diseases, criminal matters (Sec 39 CrPC), and court orders are the most commonly tested examples.
• HIV/AIDS disclosure to a sexual partner = privileged communication (Supreme Court of India ruling).
• Child abuse reporting = both ethical and legal duty = privileged communication.

Diabetes Mellitus - Management & Treatment

1. Overall Goals of Management

• Achieve and maintain near-normal glycemia (individualized HbA1c target)
• Prevent or delay microvascular and macrovascular complications
• Manage cardiovascular risk factors (hypertension, dyslipidemia, obesity)
• Prevent and treat hypoglycemia
• Improve quality of life

2. Glycemic Targets

• ADA recommendation: HbA1c measured at least twice yearly in those at goal; every 3 months when not at goal or after therapy change.
• CGM (Continuous Glucose Monitoring): Recommended for all patients on insulin injections; those on oral therapy can monitor less intensively (3-5 times/week).
• Substances that interfere with HbA1c include hemoglobinopathies, hemolytic anemia - use alternative markers (fructosamine, CGM) in these cases.
• Harrison's Principles of Internal Medicine, 22e (2025)

3. Non-Pharmacological Management (Lifestyle)

• Medical Nutrition Therapy (MNT): Reduced caloric intake; limit refined carbohydrates and saturated fats; Mediterranean or DASH-style diets supported by evidence.
• Physical Activity: At least 150 min/week of moderate-intensity aerobic exercise; resistance training 2-3x/week. Exercise improves insulin sensitivity.
• Weight loss: 5-10% weight loss significantly improves glycemia in T2DM; >15% weight loss may induce remission.
• Smoking cessation: Mandatory.
• Alcohol: Moderate use may mask hypoglycemia symptoms; patients on insulin or sulfonylureas must be cautioned.

4. Pharmacological Management - Type 2 Diabetes

Step 1: At Diagnosis - Metformin + Lifestyle

• Mechanism: Reduces hepatic glucose output (inhibits gluconeogenesis); improves insulin sensitivity.
• Benefits: Effective, inexpensive, weight neutral, low hypoglycemia risk, proven CV safety, possible CV benefit.
• Dose: Start low (500 mg with meals), titrate up to 2000-2500 mg/day to minimize GI side effects.
• Contraindications: eGFR < 30 mL/min (hold if eGFR 30-45); IV contrast dye procedures (hold 48 hrs); severe hepatic disease; excessive alcohol.

"Metformin remains the consensus first line of therapy and should be started at the time of diagnosis."

• Goodman & Gilman's, p. 1061

Step 2: Add a Second Agent (If HbA1c not at goal within 2-3 months)

A. Established ASCVD (Atherosclerotic Cardiovascular Disease)

• Preferred: GLP-1 receptor agonist OR SGLT-2 inhibitor
• Liraglutide (GLP-1RA) and empagliflozin/canagliflozin (SGLT-2i) have proven CV mortality reduction in landmark trials.

B. Heart Failure (HFrEF)

• Preferred: SGLT-2 inhibitor (empagliflozin, dapagliflozin)
• SGLT-2i reduce hospitalizations for heart failure. Avoid thiazolidinediones (worsen fluid retention).

C. Diabetic Kidney Disease (CKD)

• Preferred: SGLT-2 inhibitor (empagliflozin, canagliflozin, dapagliflozin slow CKD progression)
• Do NOT initiate SGLT-2i if eGFR < 30 (stage 3b CKD).
• GLP-1 agonists also reduce renal events.

D. Obesity / Weight loss priority

• Preferred: GLP-1 RA (semaglutide, liraglutide) or Tirzepatide (GIP+GLP-1 dual agonist)
• Tirzepatide produces greater weight loss than any GLP-1RA alone.

E. Cost sensitivity / budget-conscious

• Preferred: Sulfonylurea (e.g., glimepiride, glipizide) - inexpensive, effective, but risk of hypoglycemia and weight gain.

Drug Class Summary Table

• Katzung's Basic & Clinical Pharmacology, 16th ed.; Goodman & Gilman's; Harrison's 22e

Step 3: Escalation / Triple Therapy

• If still not at goal: Add a third agent (e.g., metformin + GLP-1RA + SGLT-2i).
• If oral agents + injectables fail: Add basal insulin.
• GRADE trial evidence: Liraglutide or basal insulin added to metformin provided slightly better glycemic control than glimepiride or sitagliptin.

5. Insulin Therapy

When to Start Insulin

• Type 1 DM: Always, from diagnosis.
• Type 2 DM: When oral agents fail; HbA1c markedly elevated at diagnosis (e.g., > 10-11%); symptomatic hyperglycemia; hospitalization; pregnancy.

Insulin Types & Pharmacokinetics

• Harrison's Principles of Internal Medicine, 22e (2025)

Insulin Regimens

• Basal insulin (once daily long-acting): First insulin added in T2DM.
• Basal-bolus regimen (MDI - Multiple Daily Injections): Standard for T1DM; basal + rapid-acting with each meal.
• CSII (Insulin pump): Continuous subcutaneous infusion; allows finer control.
• AID (Automated Insulin Delivery / Closed-loop / "Artificial pancreas"): CGM-linked pump with algorithm that auto-adjusts infusion; reduces hypoglycemia.

6. Type 1 Diabetes - Specific Management

• Insulin is mandatory - no oral agents as monotherapy.
• Intensive management targets HbA1c near 7%.
• DCCT trial established that tight glycemic control reduces microvascular complications by ~60%.
• Metformin may be used as adjunct in some T1DM patients to reduce insulin dose.
• Emerging: Anti-CD3 monoclonal antibodies (teplizumab) in Stage 2 T1DM can delay onset by ~2 years (FDA approved 2022).

7. Special Situations

Perioperative Management

• Hold GLP-1 RAs before elective procedures (risk of gastroparesis, aspiration).
• Hold SGLT-2 inhibitors 3-4 days before major surgery (risk of euglycemic DKA).
• Target glucose 140-180 mg/dL in hospitalized/ICU patients.

Renal Impairment

• eGFR < 30: Stop metformin, SGLT-2i.
• Dose adjust DPP-4 inhibitors.
• Insulin remains usable but hypoglycemia risk increases as insulin clearance decreases.

Heart Failure

• Avoid TZDs (fluid retention).
• Prefer SGLT-2i.

Pregnancy (Gestational Diabetes / GDM)

• First line: Diet and exercise.
• Insulin if glycemic targets not met (metformin/glyburide are second-line options in some guidelines).

8. Cardiovascular & Renal Risk Management (Mandatory)

9. Monitoring & Follow-up

10. Bariatric Surgery